AN3CA Cell Line

Brief Introduction
Product List

General Information
Organism	Homo sapiens, human
Cell Line Description	AN3CA is a human endometrial adenocarcinoma cell line established in 1962 from a lymph node metastasis of a 55-year-old Caucasian female patient with endometrioid adenocarcinoma of the endometrium associated with acanthosis nigricans. The cells grow as an adherent epithelial monolayer with prominent cytoplasmic vesicles and a doubling time of approximately 45 to 55 hours. AN3CA is characterized by a homozygous PTEN truncating mutation and is microsatellite instability-high owing to defective mismatch repair, making it a standard model for PTEN-deficient endometrial cancer. Additional alterations include TP53, PIK3R1 and MAPK3 mutations. The line is negative for estrogen and progesterone receptors, is tumorigenic in nude mice and in the hamster cheek pouch, and is widely used in PARP inhibitor sensitivity studies, PI3K/AKT/mTOR pathway inhibitor screening, and endometrial cancer xenograft modeling. It remains one of the few widely available endometrial carcinoma lines carrying biallelic PTEN loss, and is used to model type I endometrioid disease with defective mismatch repair and to evaluate DNA damage response inhibitors.
Tissue	Endometrium; derived from metastatic site (lymph node)
Disease	Endometrial Adenocarcinoma (endometrioid, type I); associated with acanthosis nigricans
Morphology	Epithelial; adherent monolayer with prominent cytoplasmic vesicles
Gender	Female
Age	55 years
Ethnicity	Caucasian
Product Format	Frozen
Growth Mode	Adherent
Biosafety Level	1 (Biosafety classification is based on U.S. Public Health Service Guidelines)
Applications	1. Modeling of PTEN-deficient endometrial cancer and investigation of sensitivity to PARP inhibitors; 2. Screening of inhibitors targeting the PI3K/AKT/mTOR pathway (including rapamycin and dual mTORC1/2 inhibitors); 3. Development of xenograft models for TP53-mutant and non-endometrioid endometrial cancers; 4. Evaluation of combination therapies targeting the Ras/MAPK and PI3K pathways; 5. Biological characteristics of hormone receptor-negative endometrial cancer.
Shipped In	Dry ice
Storage Temperature	−196°C
Characteristics
Tumorigenic	Yes, forms poorly differentiated tumors in nude mice and in the hamster cheek pouch
Karyotype	Human hyperdiploid; 49 (45–50) <2n>XX, +5, +6, +7, der(3)t(1;3)(q24;p22); 14% polyploidy
Expression Markers	Negative for estrogen receptor and progesterone receptor. Positive for cytokeratin 8/18, E-cadherin and vimentin
Mycoplasma Test	Negative
Viral Status	Reverse transcriptase negative by ELISA; PCR negative for EBV, HBV, HCV, HHV-8, HIV-1, HIV-2, HTLV-1, HTLV-2, MLV and SMRV
Culture Conditions and Handling
Subculturing	1. Remove and discard the culture medium. 2. Briefly rinse the cell monolayer with PBS (Ca²⁺/Mg²⁺-free) to thoroughly remove residual serum. 3. Add 2.0 to 3.0 mL of 0.25% Trypsin–0.53 mM EDTA solution, and observe under an inverted microscope until the cell monolayer has dispersed (typically takes 2 to 5 minutes). 4. Add 6.0 to 8.0 mL of complete growth medium, and gently pipette to prepare a single-cell suspension. 5. Aliquot the cell suspension into new culture vessels.
Medium Renewal	Every 3 to 4 days
Subcultivation Ratio	Split confluent cultures at a ratio of 1:3 to 1:8 once or twice weekly; seed at 1–2 × 10⁶ cells per 25 cm².
Culture Conditions	Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C
Cryopreservation	70% complete growth medium + 20% FBS + 10% DMSO

Cat.No.	Product Name	Price
CSC-RR01020	GFP/Luc Reporter Cell Line - AN3CA	Inquiry

The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.

* For research use only. Not intended for any clinical use.

Quick Inquiry